CA1094056A - Poly-5-hydroxycytidylic acid copolymers - Google Patents
Poly-5-hydroxycytidylic acid copolymersInfo
- Publication number
- CA1094056A CA1094056A CA292,512A CA292512A CA1094056A CA 1094056 A CA1094056 A CA 1094056A CA 292512 A CA292512 A CA 292512A CA 1094056 A CA1094056 A CA 1094056A
- Authority
- CA
- Canada
- Prior art keywords
- copolymer
- acid
- weight
- molar percent
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229920001577 copolymer Polymers 0.000 title claims abstract description 69
- 239000002253 acid Substances 0.000 title claims abstract description 49
- 239000000178 monomer Substances 0.000 claims abstract description 47
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 claims abstract description 16
- 238000005893 bromination reaction Methods 0.000 claims abstract description 15
- 229930183912 Cytidylic acid Natural products 0.000 claims abstract description 14
- 230000031709 bromination Effects 0.000 claims abstract description 14
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 11
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 11
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Inorganic materials Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000000862 absorption spectrum Methods 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 230000006399 behavior Effects 0.000 claims 2
- 230000000875 corresponding effect Effects 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 20
- 108091033319 polynucleotide Proteins 0.000 abstract description 9
- 102000040430 polynucleotide Human genes 0.000 abstract description 9
- 239000002157 polynucleotide Substances 0.000 abstract description 9
- 230000000840 anti-viral effect Effects 0.000 abstract description 7
- 230000007062 hydrolysis Effects 0.000 abstract description 6
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000000203 mixture Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 241000700605 Viruses Species 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000012535 impurity Substances 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 4
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 3
- 241000710772 Yellow fever virus Species 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 229940051021 yellow-fever virus Drugs 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000011176 biofiber Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
- 241000722946 Acanthocybium solandri Species 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101100260020 Caenorhabditis elegans mls-1 gene Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- BSKZDJXVMPWPRA-UHFFFAOYSA-N O.[Br] Chemical compound O.[Br] BSKZDJXVMPWPRA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- -1 nucleoside monophosphates Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
- C08G79/02—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing phosphorus
- C08G79/04—Phosphorus linked to oxygen or to oxygen and carbon
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB53822/76 | 1976-12-23 | ||
| GB53822/76A GB1545099A (en) | 1976-12-23 | 1976-12-23 | Poly-5-hydroxycytidylic acid copolymers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1094056A true CA1094056A (en) | 1981-01-20 |
Family
ID=10469095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA292,512A Expired CA1094056A (en) | 1976-12-23 | 1977-12-06 | Poly-5-hydroxycytidylic acid copolymers |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4151350A (enExample) |
| JP (1) | JPS53111400A (enExample) |
| CA (1) | CA1094056A (enExample) |
| DE (1) | DE2756713A1 (enExample) |
| FR (1) | FR2375254A1 (enExample) |
| GB (1) | GB1545099A (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1435571A (en) * | 1973-04-02 | 1976-05-12 | Searle & Co | Polynucleotides |
| JPS518295A (en) * | 1974-07-12 | 1976-01-23 | Kojin Kk | 55 hidorokishi 2*2** saikuroshichijin mataha sonoennoseizohoho |
-
1976
- 1976-12-23 GB GB53822/76A patent/GB1545099A/en not_active Expired
-
1977
- 1977-12-05 US US05/857,851 patent/US4151350A/en not_active Expired - Lifetime
- 1977-12-06 CA CA292,512A patent/CA1094056A/en not_active Expired
- 1977-12-20 DE DE19772756713 patent/DE2756713A1/de not_active Withdrawn
- 1977-12-22 JP JP15500977A patent/JPS53111400A/ja active Pending
- 1977-12-23 FR FR7739093A patent/FR2375254A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DE2756713A1 (de) | 1978-07-13 |
| FR2375254B1 (enExample) | 1981-01-16 |
| FR2375254A1 (fr) | 1978-07-21 |
| JPS53111400A (en) | 1978-09-28 |
| US4151350A (en) | 1979-04-24 |
| GB1545099A (en) | 1979-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR940004065B1 (ko) | 고순도 아카르보스의 제조방법 | |
| US4636489A (en) | Modified protease inhibitors, process for their preparation, and pharmaceutical compositions prepared therefrom | |
| GB2193631A (en) | Stable granulocyte colony stimulating factor composition | |
| Schuster et al. | Reaction differences between tobacco mosaic virus and its free ribonucleic acid with nitrous acid | |
| EP0869789A1 (en) | Antiviral agent | |
| US3987192A (en) | Compositions and process of treatment | |
| WO1998034603A1 (en) | Use of betulin and analogs thereof to treat herpesvirus infection | |
| EP0533902A1 (en) | A method for inhibition of retroviral replication | |
| CA2359674A1 (en) | Chain-shortened polynucleotide and method for preparation thereof | |
| EP0495116B1 (en) | Anti-human immunodeficiency virus agent | |
| RU2071323C1 (ru) | Противовирусный препарат "полирем" | |
| AU3570489A (en) | Stable compositions containing esmolol hydrochloride for cardiac conditions | |
| KR0143084B1 (ko) | 항-hiv 작용을 가진 헤파린단편 및 분획 | |
| EP0928306A1 (en) | Antiviral linear polymers | |
| CA1094056A (en) | Poly-5-hydroxycytidylic acid copolymers | |
| EP0821692B1 (en) | Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof | |
| JPH0618786B2 (ja) | 医薬組成物 | |
| KR960010438B1 (ko) | 항-hiv제 | |
| JPS5841817A (ja) | 抗ウイルス性α，α−ジアルキルアダマンチルエチルアミン | |
| EP0012495B1 (en) | Pharmaceutical composition comprising a water soluble salt of amoxycillin and polyvinylpyrrolidone, and a vial containing a unit dose of said composition | |
| EP2077847B1 (en) | Sucralose monolaurate and sucralose monomyristate, pharmaceutical formulations, diagnostic kits and methods of treatment | |
| EP0910390B1 (en) | Pharmaceutical compositions containing alkylaryl polyether alcohol polymer | |
| CN118766918A (zh) | m-AMSA或其衍生物在制备预防和/或治疗非洲猪瘟病毒感染的药物中的用途 | |
| EP0167936A2 (en) | Use of actinonin as an immunopotentiator | |
| US3935185A (en) | Polynucleotides of poly(5-hydroxycytidylic acids) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry | ||
| MKEX | Expiry |
Effective date: 19980120 |